Theodore Holman (University of California, Santa Cruz)
Ajit Jadhav (NCATS)
Anton Simeonov (NCATS)
David Maloney (NCATS)
Ganesha Rai Bantukallu (NCATS)
Steven Kelly (Swansea University)
This technology includes a newly designed chemical molecule that is both an antifungal agent, by inhibiting CYP51,
and an anti-inflammatory agent, by inhibiting 5-lipoxygenase, for the treatment of dandruff. Both of these properties would be useful for antifungal treatments, and both of these attributes are required to combat dandruff. However,
typical therapies involve treating the infection and inflammation separately.
Utilized for the treatment of dandruff.
Single agent therapy for dandruff with a dual mechanism.